Manipulating hTERT splicing in lung cancer cells.

操纵肺癌细胞中的 hTERT 剪接。

基本信息

  • 批准号:
    9764287
  • 负责人:
  • 金额:
    $ 24.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-01 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The vast majority (>85%) of human cancers use telomerase as the primary telomere length maintenance mechanism. My long-term goal is to establish an independent research laboratory, where I will elucidate the molecular mechanisms by which alternative splicing plays a role in telomere length maintenance mechanisms. This basic biological information will be important for my long-term goals for designing telomerase specific cancer therapeutics. The K99/R00 career award will help me in achieving my goals as a research scientist by advancing my training in: gene expression regulation, alternative splicing, next generation sequencing, and molecular biology under the co-mentorship of Dr. Woodring Wright, as well as cancer cell biology and models of cancer cell phenotypes under the co-mentorship of Dr. Jerry Shay. This training and guidance will compliment my previous training in gene expression, muscle biology, and cell signaling. The scientific environment at UT Southwestern Medical Center is extremely stimulating and will provide me with the facilities necessary for the completion of the mentored phase of this project and will prepare me to transition smoothly into the independent faculty phase. hTERT expression is developmentally regulated and has several splice variants. Only full-length hTERT mRNA produces catalytically active telomerase. Upon differentiation into mature tissue telomerase activity is down-regulated and only non-catalytically active hTERT splice variants remain. However, upon transformation to cancer, the majority of cancer types express full-length hTERT and have functional telomerase activity that helps to maintain the already very short telomeres in precancerous lesions. The transcriptional activation of hTERT has been widely studied, but the regulation of hTERT alternative splicing is almost entirely unknown. In Aim 1, during the K99 phase, I will define the role of NOVA1 that I identified in two different RNAi screens, in the regulation of hTERT splicing, telomere length, and telomerase activity. I will determine if NOVA1 binds hTERT pre-mRNA directly (CLIP) or in a protein complex (RIP). I will also define the role of NOVA1 in cancer cell alternative splicing by RNA sequencing. In Aim 2, during the K99 phase, I will use two xenograft models of tumor progression to determine if reduced levels of NOVA1 result in less metastases and tumor progression via inhibition of telomerase. During the R00 phase, Aim 3, I will characterize the regulation of NOVA1's 3'UTR in cancer cells and the potential of using a NOVA1 3'UTR reporter for small molecule screening to find a novel telomerase inhibitor. I will also continue to decipher the "hTERT splicing code" I discovered during my mentored phase with the goal of finding novel means to inhibit telomerase in cancer. These studies should lead to a robust research program into how alternative spicing participates and regulates telomere length maintenance mechanisms in cancer cells.
 描述(申请人提供):绝大多数(>85%)人类癌症使用端粒酶作为维持端粒长度的主要机制。我的长期目标是建立一个独立的研究实验室,在那里我将阐明选择性剪接在端粒长度维持机制中发挥作用的分子机制。这些基本的生物学信息对于我设计端粒酶特异性癌症疗法的长期目标将是重要的。K99/R00职业生涯奖将帮助我实现作为一名研究科学家的目标,促进我在以下方面的培训:在Woodring Wright博士的共同指导下,基因表达调控、选择性剪接、下一代测序和分子生物学,以及在曾傑瑞·Shay博士的共同指导下,癌细胞生物学和癌细胞表型模型。这次培训和指导将补充我之前在基因表达、肌肉生物学和细胞信号方面的培训。德克萨斯大学西南医学中心的科学环境非常令人兴奋,将为我完成这个项目的指导阶段提供必要的设施,并为我顺利过渡到独立教员阶段做好准备。HTERT的表达受发育调节,有几种剪接变体。只有全长hTERT mRNA才能产生催化活性的端粒酶。在分化为成熟组织后,端粒酶活性下调,仅保留非催化活性的hTERT剪接变体。然而,在转化为癌症后,大多数类型的癌症表达全长hTERT,并具有功能性端粒酶活性,有助于在癌前病变中维持已经非常短的端粒。HTERT的转录激活已被广泛研究,但hTERT选择性剪接的调控几乎完全未知。在目标1中,在K99阶段,我将定义我在两个不同的RNAi屏幕中发现的NOVA1在调节hTERT剪接中的作用, 端粒长度和端粒酶活性。我将确定NOVA1是直接结合hTERT前-mRNA(CLIP)还是在蛋白质复合体中结合(RIP)。我还将通过RNA测序确定NOVA1在癌细胞选择性剪接中的作用。在目标2中,在K99阶段,我将使用两种肿瘤进展的异种移植模型来确定NOVA1水平的降低是否通过抑制端粒酶来减少转移和肿瘤进展。在R00阶段,目标3,我将表征NOVA1‘S 3’UTR在癌细胞中的调节,以及使用NOVA1‘3’UTR报告进行小分子筛选以寻找新的端粒酶抑制物的可能性。我还将继续破译我在指导阶段发现的“hTERT剪接密码”,目的是找到抑制癌症端粒酶的新方法。这些研究应该导致一个强有力的研究计划,研究替代香料如何参与和调节癌细胞中的端粒长度维持机制。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Acute Exercise Regulates hTERT Gene Expression and Alternative Splicing in the hTERT-BAC Transgenic Mouse Model.
  • DOI:
    10.1249/mss.0000000000002868
  • 发表时间:
    2022-06-01
  • 期刊:
  • 影响因子:
    4.1
  • 作者:
    Slusher, Aaron L.;Kim, Jeongjin J. J.;Ribick, Mark;Ludlow, Andrew T.
  • 通讯作者:
    Ludlow, Andrew T.
Droplet Digital TRAP (ddTRAP): Adaptation of the Telomere Repeat Amplification Protocol to Droplet Digital Polymerase Chain Reaction.
Droplet Digital TRAP (ddTRAP):将端粒重复扩增方案应用于 Droplet Digital 聚合酶链式反应。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew Todd Ludlow其他文献

Andrew Todd Ludlow的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew Todd Ludlow', 18)}}的其他基金

Manipulating hTERT splicing in lung cancer cells.
操纵肺癌细胞中的 hTERT 剪接。
  • 批准号:
    9267141
  • 财政年份:
    2016
  • 资助金额:
    $ 24.3万
  • 项目类别:

相似海外基金

Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
  • 批准号:
    573541-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 24.3万
  • 项目类别:
    University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
  • 批准号:
    2744317
  • 财政年份:
    2022
  • 资助金额:
    $ 24.3万
  • 项目类别:
    Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
  • 批准号:
    MR/V010948/1
  • 财政年份:
    2021
  • 资助金额:
    $ 24.3万
  • 项目类别:
    Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
  • 批准号:
    10019570
  • 财政年份:
    2019
  • 资助金额:
    $ 24.3万
  • 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
  • 批准号:
    10223370
  • 财政年份:
    2019
  • 资助金额:
    $ 24.3万
  • 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
  • 批准号:
    10455108
  • 财政年份:
    2019
  • 资助金额:
    $ 24.3万
  • 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
  • 批准号:
    255762
  • 财政年份:
    2012
  • 资助金额:
    $ 24.3万
  • 项目类别:
    Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
  • 批准号:
    20790351
  • 财政年份:
    2008
  • 资助金额:
    $ 24.3万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
  • 批准号:
    19370021
  • 财政年份:
    2007
  • 资助金额:
    $ 24.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
  • 批准号:
    7131841
  • 财政年份:
    2006
  • 资助金额:
    $ 24.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了